Drug intelligence / Profile preview

estradiol + norethindrone acetate

Development stage
Approved
Lead developer
Novo Nordisk
Modality
Small Molecules
Administration
Oral
01

Overview

1 mg estradiol / 0.5 mg norethindrone acetate is a continuous combined oral estrogen/progestin hormonal combination therapy. It contains estradiol, a bioidentical estrogen, and norethindrone acetate, a synthetic progestin. This combination is widely approved and marketed as hormone replacement therapy (HRT) in postmenopausal women with an intact uterus to treat moderate-to-severe vasomotor symptoms (such as hot flashes), vulvar and vaginal atrophy, and to prevent postmenopausal osteoporosis. Additionally, in the context of AbbVie's uterine fibroid program, this specific strength of E2/NETA is co-administered as an add-back therapy with elagolix (marketed under the brand name Oriahnn) to mitigate hypoestrogenic side effects, such as bone mineral density loss and hot flushes, in premenopausal women undergoing treatment for heavy menstrual bleeding associated with uterine fibroids.

Brand names
AbigaleActivellaActivelleAmabelzCliovelleEtyqaKliovanceLopreezaMimveyTulita
Other names
1 mg estradiol / 0.5 mg norethindrone acetateE2/NETAestradiol + norethindrone acetateestradiol + norethisterone acetateestradiol and norethindrone acetateestradiol and norethisterone acetateestradiol/norethindrone acetateestradiol/norethisterone acetate
02

Targets

ESR1 (ERα)ESR2 (ERβ)PR (Progesterone receptor)

Beyond the preview

Go deeper on estradiol + norethindrone acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on estradiol + norethindrone acetate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call